{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T18:27:22Z","timestamp":1793039242422,"version":"4.5.0"},"reference-count":50,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,6,9]],"date-time":"2023-06-09T00:00:00Z","timestamp":1686268800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100015401","name":"Key Research and Development Projects of Shaanxi Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015401","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017596","name":"Natural Science Basic Research Program of Shaanxi Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100017596","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Background and aim<\/jats:title><jats:p>Sepsis is a syndromic response to infection and is associated with high mortality, thus imposing a significant global burden of disease. Although low-molecular-weight heparin (LMWH) has been recommended to prevent venous thromboembolism, its anticoagulant and anti-inflammatory effects in sepsis remain controversial. Owing to the modification of the Sepsis-3 definition and diagnostic criteria, further evaluation of the efficacy and benefit population of LMWH is required.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We performed a retrospective cohort study to assess whether LMWH improved the inflammation, coagulopathy, and clinical outcomes against Sepsis-3 and to identify the target patients. All patients diagnosed with sepsis at the First Affiliated Hospital of Xi'an Jiaotong University (the largest general hospital in northwest China) from January 2016 to December 2020 were recruited and re-evaluated using Sepsis-3 criteria.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>After 1:1 propensity score matching, 88 pairs of patients were categorized into the treatment and control groups based on subcutaneous LMWH administration. Compared with the control group, a significantly lower 28-day mortality was observed in the LMWH group (26.1 vs. 42.0%, <jats:italic>p<\/jats:italic> = 0.026) with a comparable incidence of major bleeding events (6.8 vs. 8.0%, <jats:italic>p<\/jats:italic> = 0.773). Cox regression analysis showed that LMWH administration was the independent protective factor for septic patients (aHR, 0.48; 95% CI, 0.29\u20130.81; <jats:italic>p<\/jats:italic> = 0.006). Correspondingly, the LMWH treatment group showed a significant improvement in inflammation and coagulopathy. Further subgroup analysis showed that LMWH therapy was associated with favorable outcomes in patients younger than 60 years and diagnosed with sepsis-induced coagulopathy (SIC), ISTH overt DIC, non-septic shock, or non-diabetics and in patients included in the moderate-risk group (APACHE II score 20\u201335 or SOFA score 8\u201312).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Our study results showed that LMWH improves 28-day mortality by improving inflammatory response and coagulopathy in patients meeting Sepsis-3 criteria. The SIC and ISTH overt DIC scoring systems can better identify septic patients who are likely to benefit more from LMWH administration.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2023.1157775","type":"journal-article","created":{"date-parts":[[2023,6,9]],"date-time":"2023-06-09T05:09:19Z","timestamp":1686287359000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":17,"title":["Low-molecular-weight heparin therapy reduces 28-day mortality in patients with sepsis-3 by improving inflammation and coagulopathy"],"prefix":"10.3389","volume":"10","author":[{"given":"Ze","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taotao","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danfeng","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingwen","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liangru","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianzhi","family":"Ni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weicheng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianyan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingli","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingren","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinfeng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,6,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/S0140-6736(19)32989-7","article-title":"Global, regional, and national sepsis incidence and mortality, 1990\u20132017: analysis for the global burden of disease study","volume":"395","author":"Rudd","year":"2020","journal-title":"Lancet."},{"key":"B2","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1001\/jama.2016.0287","article-title":"The third international consensus definitions for sepsis and septic shock (sepsis-3)","volume":"315","author":"Singer","year":"2016","journal-title":"JAMA."},{"key":"B3","doi-asserted-by":"publisher","first-page":"2475","DOI":"10.1111\/jth.15852","article-title":"Intracellular communication and immunothrombosis in sepsis","volume":"20","author":"Iba","year":"2022","journal-title":"J Thromb Haemost."},{"key":"B4","doi-asserted-by":"publisher","first-page":"R123","DOI":"10.1186\/cc10228","article-title":"Treatment effects of recombinant human soluble thrombomodulin in patients with severe sepsis: a historical control study","volume":"15","author":"Yamakawa","year":"2011","journal-title":"Crit Care."},{"key":"B5","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1186\/s13054-016-1415-1","article-title":"Benefit profile of anticoagulant therapy in sepsis: a nationwide multicentre registry in Japan","volume":"20","author":"Yamakawa","year":"2016","journal-title":"Crit Care."},{"key":"B6","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1111\/bjh.14885","article-title":"The role of heparin in sepsis: much more than just an anticoagulant","volume":"179","author":"Li","year":"2017","journal-title":"Br J Haematol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1056\/NEJMoa2105911","article-title":"Therapeutic anticoagulation with heparin in noncritically ill patients with Covid-19","volume":"385","author":"Lawler","year":"2021","journal-title":"N Engl J Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"2214","DOI":"10.1111\/jth.15808","article-title":"Isth guidelines for antithrombotic treatment in Covid-19","volume":"20","author":"Schulman","year":"2022","journal-title":"J Thromb Haemost."},{"key":"B9","first-page":"296","article-title":"Clinical evaluation of new therapeutic concepts in septic shock","volume":"27","author":"Martinez","year":"1966","journal-title":"Obstet Gynecol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1007\/s00134-021-06506-y","article-title":"Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021","volume":"47","author":"Evans","year":"2021","journal-title":"Intensive Care Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1016\/j.amjcard.2010.10.020","article-title":"Comparison of the effectiveness and safety of low-molecular weight heparin versus unfractionated heparin anticoagulation after heart valve surgery","volume":"107","author":"Bucci","year":"2011","journal-title":"Am J Cardiol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"3115","DOI":"10.21037\/apm-21-169","article-title":"Therapeutic effect of low-molecular-weight heparin on adult sepsis: a meta-analysis","volume":"10","author":"Li","year":"2021","journal-title":"Ann Palliat Med."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1001\/jama.286.15.1869","article-title":"Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial","volume":"286","author":"Warren","year":"2001","journal-title":"JAMA."},{"key":"B14","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1001\/jama.290.2.238","article-title":"Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial","volume":"290","author":"Abraham","year":"2003","journal-title":"JAMA."},{"key":"B15","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1056\/NEJMoa1202290","article-title":"Drotrecogin alfa (activated) in adults with septic shock","volume":"366","author":"Ranieri","year":"2012","journal-title":"N Engl J Med."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1007\/s00134-009-1483-7","article-title":"Comprehensive safety analysis of concomitant drotrecogin alfa (activated) and prophylactic heparin use in patients with severe sepsis","volume":"35","author":"Levy","year":"2009","journal-title":"Intens Care Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1055\/s-0037-1616068","article-title":"Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation","volume":"86","author":"Taylor FB","year":"2001","journal-title":"Thromb Haemost."},{"key":"B18","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1097\/01.CCM.0000202209.42491.38","article-title":"A multicenter, prospective validation of disseminated intravascular coagulation diagnostic criteria for critically ill patients: comparing current criteria","volume":"34","author":"Gando","year":"2006","journal-title":"Crit Care Med."},{"key":"B19","doi-asserted-by":"publisher","first-page":"e0129170","DOI":"10.1371\/journal.pone.0129170","article-title":"Retrospective evaluation of new chinese diagnostic scoring system for disseminated intravascular coagulation","volume":"10","author":"Wang","year":"2015","journal-title":"PLoS ONE."},{"key":"B20","doi-asserted-by":"publisher","first-page":"e017046","DOI":"10.1136\/bmjopen-2017-017046","article-title":"New criteria for sepsis-induced coagulopathy (sic) following the revised sepsis definition: a retrospective analysis of a nationwide survey","volume":"7","author":"Iba","year":"2017","journal-title":"BMJ Open."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1111\/jth.14578","article-title":"Diagnosis and management of sepsis-induced coagulopathy and disseminated intravascular coagulation","volume":"17","author":"Iba","year":"2019","journal-title":"J Thromb Haemost."},{"key":"B22","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1111\/jth.13230","article-title":"Efficacy and safety of anticoagulant therapy in three specific populations with sepsis: a meta-analysis of randomized controlled trials","volume":"14","author":"Umemura","year":"2016","journal-title":"J Thromb Haemost."},{"key":"B23","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1111\/j.1538-7836.2005.01697.x","article-title":"Treatment effects of high-dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation","volume":"4","author":"Kienast","year":"2006","journal-title":"J Thromb Haemost."},{"key":"B24","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1111\/jth.12155","article-title":"Guidance for diagnosis and treatment of dic from harmonization of the recommendations from three guidelines","volume":"11","author":"Wada","year":"2013","journal-title":"J Thromb Haemost."},{"key":"B25","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1097\/01.CCM.0000153520.31562.48","article-title":"Dynamic evolution of coagulopathy in the first day of severe sepsis: relationship with mortality and organ failure","volume":"33","author":"Dhainaut","year":"2005","journal-title":"Crit Care Med."},{"key":"B26","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1160\/TH16-08-0620","article-title":"More than an anticoagulant: do heparins have direct anti-inflammatory effects?","volume":"117","author":"Poterucha","year":"2017","journal-title":"Thromb Haemost."},{"key":"B27","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1046\/j.1365-2036.1998.00293.x","article-title":"The effect of heparin on trinitrobenzene sulphonic acid-induced colitis in the rat","volume":"12","author":"Fries","year":"1998","journal-title":"Aliment Pharmacol Ther."},{"key":"B28","doi-asserted-by":"publisher","first-page":"726630","DOI":"10.3389\/fphar.2021.726630","article-title":"Low molecular weight heparin improves the inflammatory state of acute sinusitis rats through inhibiting the Tlr4-Myd88-Nf-\u03bab signaling pathway","volume":"12","author":"Wu","year":"2021","journal-title":"Front Pharmacol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1186\/s13054-014-0563-4","article-title":"Heparin therapy reduces 28-day mortality in adult severe sepsis patients: a systematic review and meta-analysis","volume":"18","author":"Wang","year":"2014","journal-title":"Crit Care."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.3390\/jcm8111869","article-title":"A systematic summary of systematic reviews on anticoagulant therapy in sepsis","volume":"8","author":"Murao","year":"2019","journal-title":"J Clin Med."},{"key":"B31","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1097\/CCM.0000000000002074","article-title":"Sepsis pathophysiology, chronic critical illness, and persistent inflammation-immunosuppression and catabolism syndrome","volume":"45","author":"Mira","year":"2017","journal-title":"Crit Care Med."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.3389\/fimmu.2018.01511","article-title":"Chronic critical illness and the persistent inflammation, immunosuppression, and catabolism syndrome","volume":"9","author":"Hawkins","year":"2018","journal-title":"Front Immunol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"127","DOI":"10.2337\/dc21-1050","article-title":"Glycemic control and risk of sepsis and subsequent mortality in type 2 diabetes","volume":"45","author":"Balintescu","year":"2022","journal-title":"Diabetes Care."},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1128\/mSphere.00052-19","article-title":"A cohort study of the impact of carbapenem-resistant enterobacteriaceae infections on mortality of patients presenting with sepsis","author":"Sabino","year":"2019","journal-title":"mSphere."},{"key":"B35","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s13054-018-2001-5","article-title":"The use of mid-regional proadrenomedullin to identify disease severity and treatment response to sepsis - a secondary analysis of a large randomised controlled trial","volume":"22","author":"Elke","year":"2018","journal-title":"Crit Care."},{"key":"B36","doi-asserted-by":"publisher","first-page":"728","DOI":"10.3390\/jcm8050728","article-title":"Advance in the management of sepsis-induced coagulopathy and disseminated intravascular coagulation","volume":"8","author":"Iba","year":"2019","journal-title":"J Clin Med."},{"key":"B37","doi-asserted-by":"publisher","first-page":"604","DOI":"10.3892\/etm.2013.1466","article-title":"Low-dose heparin as treatment for early disseminated intravascular coagulation during sepsis: a prospective clinical study","volume":"7","author":"Liu","year":"2014","journal-title":"Exp Ther Med."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1076029619839154","DOI":"10.1177\/1076029619839154","article-title":"The treatment intensity of anticoagulant therapy for patients with sepsis-induced disseminated intravascular coagulation and outcomes: a multicenter cohort study","volume":"25","author":"Kudo","year":"2019","journal-title":"Clin Appl Thromb Hemost."},{"key":"B39","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1002\/ams2.326","article-title":"A summary of the Japan septic disseminated intravascular coagulation study","volume":"5","author":"Hayakawa","year":"2018","journal-title":"Acute Med Surg."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1076029619835055","DOI":"10.1177\/1076029619835055","article-title":"Optimal timing and early intervention with anticoagulant therapy for sepsis-induced disseminated intravascular coagulation","volume":"25","author":"Yamakawa","year":"2019","journal-title":"Clin Appl Thromb Hemost."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.1055\/s-0039-1693740","article-title":"Identifying sepsis populations benefitting from anticoagulant therapy: a prospective cohort study incorporating a restricted cubic spline regression model","volume":"119","author":"Yamakawa","year":"2019","journal-title":"Thromb Haemost."},{"key":"B42","doi-asserted-by":"publisher","first-page":"111423","DOI":"10.1016\/j.exger.2021.111423","article-title":"Do inflammaging and coagul-aging play a role as conditions contributing to the co-occurrence of the severe hyper-inflammatory state and deadly coagulopathy during Covid-19 in older people?","volume":"151","author":"Xu","year":"2021","journal-title":"Exp Gerontol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"25984","DOI":"10.1038\/srep25984","article-title":"Efficacy and safety of low-molecular-weight heparin in patients with sepsis: a meta-analysis of randomized controlled trials","volume":"6","author":"Fan","year":"2016","journal-title":"Sci Rep."},{"key":"B44","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1097\/CCM.0000000000000763","article-title":"The efficacy and safety of heparin in patients with sepsis: a systematic review and metaanalysis","volume":"43","author":"Zarychanski","year":"2015","journal-title":"Crit Care Med."},{"key":"B45","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1007\/s12098-017-2432-z","article-title":"Platelet distribution width to platelet count ratio as an index of severity of illness","volume":"85","author":"Purbiya","year":"2018","journal-title":"Indian J Pediatr."},{"key":"B46","doi-asserted-by":"publisher","first-page":"1862","DOI":"10.1002\/jmv.24547","article-title":"Prognostic impact of platelet distribution width in patients with crimean-congo hemorrhagic fever","volume":"88","author":"Yilmaz","year":"2016","journal-title":"J Med Virol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"9056363","DOI":"10.1155\/2022\/9056363","article-title":"Prognostic value of platelet to lymphocyte ratio in sepsis: a systematic review and meta-analysis","volume":"2022","author":"Wang","year":"2022","journal-title":"Biomed Res Int."},{"key":"B48","doi-asserted-by":"publisher","first-page":"106145","DOI":"10.1016\/j.intimp.2019.106145","article-title":"Prognostic value of an inflammatory biomarker-based clinical algorithm in septic patients in the emergency department: an observational study","volume":"80","author":"Zhao","year":"2020","journal-title":"Int Immunopharmacol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.5858\/arpa.2020-0471-SA","article-title":"Predicting disease severity and outcome in covid-19 patients: a review of multiple biomarkers","volume":"144","author":"Tjendra","year":"2020","journal-title":"Arch Pathol Lab Med."},{"key":"B50","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1080\/00325481.2022.2140535","article-title":"The systemic immune-inflammation index in predicting sepsis mortality","volume":"135","author":"Mangalesh","year":"2022","journal-title":"Postgrad Med."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2023.1157775\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,9]],"date-time":"2023-06-09T05:09:23Z","timestamp":1686287363000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2023.1157775\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,9]]},"references-count":50,"alternative-id":["10.3389\/fmed.2023.1157775"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2023.1157775","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,9]]},"article-number":"1157775"}}